Celgene opts in for Juno's CD19 programs

Celgene Corp. (NASDAQ:CELG) exercised its option to develop and commercialize CD19-directed candidates from Juno Therapeutics Inc. (NASDAQ:JUNO)

Read the full 178 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE